TY - JOUR AU - Fukuyama, Tomoki AU - Ehling, Sarah AU - Wilzopolski, Jenny AU - Bäumer, Wolfgang PY - 2018 DA - 2018/07/03 TI - Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model JO - BMC Pharmacology and Toxicology SP - 37 VL - 19 IS - 1 AB - Topical administration of PR022, 0.05% hypochlorous acid (HOCl) in gel has been demonstrated to be beneficial in a chronic murine atopic dermatitis model. In a follow up study we tested a higher concentration (0.1%) of PR022 HOCl gel in comparison to the Janus kinase inhibitor tofacitinib, both of which are currently in clinical phase studies for treatment of human atopic dermatitis. SN - 2050-6511 UR - https://doi.org/10.1186/s40360-018-0232-3 DO - 10.1186/s40360-018-0232-3 ID - Fukuyama2018 ER -